SCHEMBL775197

SCHEMBL775197

Cc1ccc(O)c(CN)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 1/20 0.59
TRPA1 O75762 1/20 0.52
ALOX15 P16050 3/20 0.52
HSD17B10 Q99714 2/20 0.52
ALDH1A1 P00352 1/20 0.52
TP53 P04637 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
HTT P42858 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
ALOX12 P18054 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CSNK2A1 P68400 1/20 0.42
BACE1 P56817 2/20 0.41
SLC6A2 P23975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29509787 1.00 AMY1A (0.59) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL10440353 0.82 TRPA1 (0.52) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL29402131 0.81 AMY1A (0.83) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL29621432 0.81 AMY1A (0.83) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL9008165 0.81 AMY1A (0.63) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL50622 0.81 AMY1A (0.83) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL29395472 0.79 AMY1A (0.61) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL1023280 0.79 AMY1A (0.61) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
SCHEMBL255991 0.79 AMY1A (0.61) AMY1ATRPA1ALOX15HSD17B10ALDH1A1
Methyl Alcohol SCHEMBL3081581 0.79 AMY1A (0.80) AMY1ATRPA1ALOX15HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615015-B1 GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING ATHEROSCLEROSIS UNIV VANDERBILT (US) 2024-03-13 EP claimed
US-20250214939-A1 METHOD FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS VANDERBILT UNIVERSITY 2025-07-03 US disclosed
US-20250034093-A1 METHOD FOR TREATING LUPUS WITH GAMMA-KETOALDEHYDE SKAVENGERS VANDERBILT UNIVERSITY 2025-01-30 US disclosed
EP-3334464-B1 MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING MASSACHUSETTS GEN HOSPITAL (US) 2024-04-10 EP disclosed
EP-2731597-B1 METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS UNIV VANDERBILT (US) 2023-12-20 EP disclosed
US-20230355549-A1 METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS VANDERBILT UNIVERSITY 2023-11-09 US disclosed
US-20230355549-A1 METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS VANDERBILT UNIVERSITY 2023-11-09 US disclosed
US-20230330049-A1 COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER MTI BIOTECH, INC. 2023-10-19 US disclosed
US-20230330049-A1 COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER MTI BIOTECH, INC. 2023-10-19 US disclosed
US-11696903-B2 Compounds and methods for scavenging dicarbonyl electrophiles VANDERBILT UNIVERSITY (US) 2023-07-11 US disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed
US-20060106256-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2006-05-18 US disclosed
EP-1503980-A2 SUBSTITUTED HYDROXYETHYLAMINES Elan Pharmaceuticals, Inc. (US) 2005-02-09 EP disclosed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP disclosed
WO-2003072535-A2 SUBSTITUTED HYDROXYETHYLAMINES ELAN PHARMACEUTICALS, INC. (US) 2003-09-04 WO disclosed
US-20020128255-A1 Compounds to treat alzheimer's disease PHARMACIA & UPJOHN COMPANY 2002-09-12 US disclosed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128255-A1 Compounds to treat alzheimer's disease PSEN2, PSEN1, APP AMY1A 383/4885TRPA1 3165/4885ALOX15 1351/4885
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT AMY1A 1203/4885TRPA1 2601/4885ALOX15 1151/4885
US-20250034093-A1 METHOD FOR TREATING LUPUS WITH GAMMA-KETOALDEHYDE SKAVENGERS SSB, GLO1, HMGCR AMY1A 1963/4885TRPA1 4150/4885ALOX15 319/4885
US-20250214939-A1 METHOD FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS NFKBIA, PTGS1, HMGCR AMY1A 1729/4885TRPA1 2382/4885ALOX15 204/4885
US-20230355549-A1 METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS FABP2, SI, MLN AMY1A 2617/4885TRPA1 3226/4885ALOX15 621/4885
US-20230330049-A1 COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER GGT1, GGH, AKR7A2 AMY1A 452/4885TRPA1 4358/4885ALOX15 510/4885
US-20060106256-A1 Substituted hydroxyethylamines HNMT, PNMT, BCHE AMY1A 2198/4885TRPA1 4445/4885ALOX15 2901/4885
US-11696903-B2 Compounds and methods for scavenging dicarbonyl electrophiles OGG1, LGMN, GLO1 AMY1A 1500/4885TRPA1 1725/4885ALOX15 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.